Percutaneous left atrial appendage closure technology for stroke prevention in patients with atrial fibrillation has significantly advanced in the past 2 decades. Several devices are under clinical investigation, and a few have already received Conformité Européene (CE)-mark approval and are available in many countries. The WATCHMAN device (Boston Scientific, Natick, Massachusetts) has the most supportive data and is under evaluation by the U.S. Food and Drug Administration for warfarin-eligible patients. The Amplatzer Cardiac Plug (St. Jude Medical, Plymouth, Minnesota) has a large real-world experience over the past 5 years, and a randomized trial comparing Amplatzer Cardiac Plug with the WATCHMAN device is anticipated in the near future. The Lariat procedure (SentreHEART Inc., Redwood City, California) has also gained interest lately, but early studies were concerning for high rates of serious pericardial effusion and major bleeding. The current real-world experience predominantly involves patients who are not long-term anticoagulation candidates or who are perceived to have high bleeding risks. This pattern of practice is expected to change when the U.S. with landmark meta-analysis showing 64% stroke reduction and 26% mortality reduction with warfarin (8,9). However, a significant proportion (30% to 50%) of eligible patients do not receive OAC due to absolute contraindications or perceived risks of bleeding (10).
A trial fibrillation (AF) is estimated to affect 1.5% to 2% of the general population, and the prevalence is projected to increase to 12.1 million by 2030 in the United States (1) . Unfortunately, AF is a major cause of stroke, increasing ischemic stroke risk by 5-fold, and is responsible for 15% of all strokes and 30% of strokes in patients age >80 years (2, 3) . Strokes associated with AF are also more severe, with victims having a 50% greater likelihood of becoming disabled or handicapped and >50% likelihood of death (4, 5) . Accordingly, stroke prevention with anticoagulation is among the main pillars of AF management, and anticoagulation guidelines have become more stringent. The Canadian Cardiovascular Society recommends anticoagulation for CHADS 2 (congestive heart failure history, hypertension history, age $75 years, diabetes mellitus history, stroke or transient ischemic attack symptoms previously) $1 and the European Society of Cardiology recommends it for CHA 2 DS 2 -VASc (congestive heart failure, hypertension, age $75 years, age 65 to 74 years, diabetes mellitus, stroke/transient ischemic attack/thromboembolism, vascular disease, sex female) $1 (6,7).
Several randomized placebo-controlled trials have demonstrated that oral anticoagulation (OAC) is highly effective in preventing thromboembolism with AF, with landmark meta-analysis showing 64% stroke reduction and 26% mortality reduction with warfarin (8, 9) . However, a significant proportion (30% to 50%) of eligible patients do not receive OAC due to absolute contraindications or perceived risks of bleeding (10) .
Long-term therapy with warfarin or novel oral anticoagulation (NOAC) is associated with lifetime major bleeding risks of 2.1% to 3.6% per year in recent clinical trials (11) (12) (13) . Although intracranial hemorrhage is consistently lower with NOAC, the overall risk of major bleeding is not diminished with dabigatran or rivaroxaban compared with warfarin (12, 13) . Apixaban was the only agent that reduced major bleeding (11) .
Other concerns and contraindications with OAC include patients with renal and liver dysfunctions (for NOAC), high risk of falls, noncompliance, and those requiring dual antiplatelet therapy after stenting. For warfarin, there are additional issues with drug and diet interaction, the need for monitoring, and a narrow therapeutic window with time in therapeutic range of only 50% to 60% (14, 15) .
Even with the relatively well-tolerated NOAC, the proportion of patients discontinuing NOAC during study follow-up was 15% to 25% (11) (12) (13) . There is also residual stroke risk of 2% to 5% annually despite optimal anticoagulation (16) . These challenges have led to devicebased therapies for nonvalvular AF.
Transesophageal echocardiography (TEE), autopsy, and surgical reports confirmed that >90% of nonrheumatic AF-related left atrial thrombi were isolated to, or originated from, the left atrial appendage (LAA) (17) . Thus, mechanical approaches to exclude the LAA from systemic circulation were explored, and early attempts by surgical removal or ligation of LAA developed over 60 years ago were limited by the invasiveness and by significant rates of incomplete exclusion that were associated with increased stroke risks (18, 19) . Minimally invasive approaches have been developed over the past 2 decades and can be broadly divided into endocardial and epicardial devices ( Table 1) . This paper reviews contemporary percutaneous LAA closure, with in-depth discussions of the procedural techniques and clinical outcomes of leading devices.
INDICATIONS FOR PERCUTANEOUS LAA CLOSURE
The current indications for percutaneous LAA closure vary geographically. Recently, the European Society of Cardiology implemented a class IIB recommendation for patients with high stroke risk and contraindications to long-term OAC (7) . The majority of procedures performed in Europe adhere to this guideline as reported by Tzikas (20) . Among w1,000
LAA closures, 74% were for patients with major bleeding or at high bleeding risk. Other indications included coronary stenting (23%), drug interaction (18%), stroke on warfarin (16%), renal or hepatic disease (13%), labile international normalized ratio (7%), and risk of falls (7%). In Canada, LAA closure is generally restricted to patients with CHADS 2 6.6%) with 5-year follow-up (22) . Despite this promising early result, the device was withdrawn from the market for commercial reasons. AMPLATZER CARDIAC PLUG. Early adopters of percutaneous LAA closure in Europe attempted nondedicated Amplatzer devices after the PLAATO device was discontinued as there was no other option (23, 24) . However, the incidence of embolization was high (12%), although the efficacy endpoints were similar to dedicated devices for successfully-implanted devices (24) . The dedicated Amplatzer Cardiac Plug ACP has to be manually loaded onto the delivery cable, but the Amulet comes pre-loaded on the There are 3 radio-opaque marker bands (33, 27 , and 21 mm) on the distal sheath, which should be aligned to the left atrial appendage (LAA)
"ostium" according to the selected device. PTFE ¼ polyethylene terephthalate.
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Of note, the LAA measurements are usually wider at the long axis view (corresponding to caudal projection on fluoroscopy) compared to the short axis (corresponding to the right anterior oblique [RAO] cranial).
Pre-procedural cardiac computed tomography angiography (CCTA) is also useful to examine LAA anatomy and dimension, given the superior spatial resolution and 3-dimensionality. Moreover, CCTA is good for ruling out LAA thrombi, especially when delayed imaging is acquired (negative predictive value 100%) (26) . Thus, CCTA can become a noninvasive alternative to TEE in experienced CCTA centers and is increasingly routinely performed prior to LAA closures (27) . Saw and Lempereur
The appropriately-sized access sheath is then safely advanced to the left upper pulmonary vein ostium.
To allow easier access, the venous access should be well-dilated, and the sheath gently rotated during advancement to ensure coaxial approach while crossing the interatrial septum.
For the WATCHMAN device, the 14-F access sheath is advanced deep into the LAA using a pigtail ( 
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IMPLANTATION TECHNIQUES FOR LARIAT
A pre-operative CCTA is necessary to exclude large (>40 mm) appendages and other anatomic variants 
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The procedure was well described by Bartus et al. 
93.2% of cases, the first device selected was implanted. With follow-up TEE, the closure rate (<3 mm residual flow) was 97.6%. The rate of periprocedural major adverse events (7-day death, ischemic stroke, systemic embolism, and procedure-or device-related complications requiring major cardiovascular or endovascular intervention) was 4.1% (mortality 0.6%, pericardial tamponade 1.2%, device embolization 0.2%, stroke 0.7%). The observed annual stroke rate was 2.1%, which was 63% lower than the expected 5.6% stroke rate based on CHA 2 DS 2 -VASc score, similar to other smaller registries (24, 39, 41) .
The U.S. pivotal ACP randomized-controlled trial commenced enrollment in early 2013, randomizing AF patients with CHADS 2 $2 to ACP versus anticoagulation (warfarin or dabigatran) in a 2:1 ratio.
However, due to slow enrollment and imminent FDA approval of WATCHMAN, this study was discontinued in December 2013 after enrollment of w80 patients.
The study is being redesigned, and it is anticipated that the new randomized study will involve a noninferiority comparison to the WATCHMAN device.
LARIAT. The first published single-center experience with the Lariat procedure included 89 patients in Poland (25) . The mean age was 62 years, CHADS 2 score was 1.9, and CHA 2 DS 2 -VASc was 2. (41), and leak <3 mm occurs in 0% to 16% of cases (35, 37, 39) . The ACP's low incidence of leak is presumably related to the doubledisk design. Residual leak has also been demonstrated with the Lariat procedure, with variable reported incidence from 2% to 22% at follow-up TEE (25, 44 Figure 5 ). However, LAA anatomy is highly variable and may have a combination of these characteristics. We pay particular attention to the anatomy at intended landing zones evaluating for sphericity, pectinate ridges, trabeculations, diverticula, and additional lobes.
Detailed measurements are taken at the orifice, intended landing zone, and available depth ( Figure 5 ). In general, both leading devices can accommodate over 95% of LAA anatomy. The LAA size is an Tables 1 and 2 .
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